Liquid Biopsy
New Challenges in the era of Immunotherapy and Precision Oncology
- 1st Edition - November 3, 2022
- Imprint: Academic Press
- Editors: Antonio Russo, Ettore Capoluongo, Antonio Galvano, Antonio Giordano
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 2 7 0 3 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 7 1 1 - 4
Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their… Read more
Purchase options
Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.
The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy.
The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy.
- Presents a “highlights section” in every chapter to help readers summarize the main aspects discussed
- Encompasses case reports to guide the reader on applying what they read in their clinical practice
- Includes several tables and figures specially created for the book to illustrate the meaning of what is expressed in the text
Cancer researchers, medical scientists, clinicians, graduate students
1. What is precision medicine in oncology?2. Liquid biopsy: a right tool in a right context?3. Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology4. Current clinically validated applications of liquid biopsy5. Liquid biopsy and immunotherapy: is all that glitter gold?6. Which technology performs better? From sample volume to extraction and molecular profiling7. Early detection screening: myth or reality?8. Molecular tumor board9. Future perspectives
- Edition: 1
- Published: November 3, 2022
- Imprint: Academic Press
- Language: English
AR
Antonio Russo
Antonio Russo, MD, is a Full Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He is President of COMU (the Italian National Board of University Medical Oncologists), Italy. He is author of more than 350 publications in peer-reviewed journals. He focused his studies on liquid biopsy since 2003.
Affiliations and expertise
Medical Oncology Director, Department of Oncology - A.O.U.P. "P. Giaccone" University Hospital, ItalyEC
Ettore Capoluongo
Ettore Capoluongo, PhD, is a Full Professor of Clinical Biochemistry and Clinical Molecular Biology and, Head of Clinical Pathology Dept. Cannizzaro Hospital, Catania (Italy). He has published over 270 publications in peer-reviewed journals.
Affiliations and expertise
Department of Molecular Medicine and Medical Biotechnologies, Universita Federico II - CEINGE, Biotecnologie Avanzate, ItalyAG
Antonio Galvano
Antonio Galvano, MD, PhD is an Associate Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He has focused his research efforts on liquid biopsies for cancer prognosis and treatment.
Affiliations and expertise
Professor of Surgery, Oncology and Stomatology, Universita degli Studi di Palermo | UNIPA · Department of Surgery, Oncology and StomaLiquid Biopsy: tology, ItalyAG
Antonio Giordano
Antonio Giordano, MD, PhD, is the Director at the Sbarro Institute at Temple University, Philadelphia (USA) and a Full Professor at University of Siena, Italy. He is best known for his discovery of cyclins, CDK9, CDK10 and Rb2/p130. He is the president and founder of the Sbarro Health Research Organization (SHRO), Philadelphia (USA). He has published over 600 publications in peer-reviewed journals.
Affiliations and expertise
Director of Sbarro Institute for Cancer Research and Molecular Medicine, and Center of Biotechnology College of Science and Technology, Temple University, USARead Liquid Biopsy on ScienceDirect